Arrowhead to Present at 10th Annual Meeting of the Oligonucleotide Therapeutics Society
PASADENA, Calif.–(BUSINESS WIRE)–
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical
company developing targeted RNAi therapeutics, today announced that the
Company is presenting at the 10th Annual Meeting of the
Oligonucleotide Therapeutics Society being held on October 12-15, 2014
in San Diego. Scheduled conference presentations include the following:
October 12, 2014 – A poster presentation titled, “Kinetics of
DPC-mediated delivery of cholesterol-conjugated RNAi triggers and their
subcellular processing in vivo,” will be presented by Christine
Woodell, Ph.D., Group Leader
October 15, 2014 – An oral presentation titled, “Development
of RNAi-based therapeutics using Dynamic Polyconjugate (DPC) delivery
technology,” will be presented by David Lewis, Ph.D., Chief
Scientific Officer
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary
Dynamic Polyconjugate delivery platform to develop targeted drugs based
on the RNA interference mechanism that efficiently silences
disease-causing genes. Arrowhead’s pipeline includes ARC-520 for chronic
hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1
antitrypsin deficiency, and partner-based programs in obesity and
oncology.
For more information please visit http://www.arrowheadresearch.com,
or follow us on Twitter @ArrowRes.
To be added to the Company’s email list and receive news directly,
please visit http://ir.arrowheadresearch.com/alerts.cfm.
Arrowhead Research Corporation
Vince Anzalone, CFA, 626-304-3400
ir@arrowres.com
or
Investor
Relations:
The Trout Group
Lauren Glaser, 646-378-2972
ir@arrowres.com
or
Media:
Russo
Partners
Martina Schwarzkopf, Ph.D., 212-845-4292
martina.schwarzkopf@russopartnersllc.com
Source: Arrowhead Research Corporation
News Provided by Acquire Media